Gold prices remain near record highs; Fed cut bets prompt weekly gains
SALT LAKE CITY - Health Catalyst, Inc. (NASDAQ:HCAT), a healthcare technology company with $316 million in annual revenue and a market capitalization of $236 million, has formed a new partnership with CyncHealth Nebraska, the state’s health information exchange, to improve the delivery of patient health information across healthcare providers, according to a press release issued Tuesday. According to InvestingPro analysis, the company maintains a GOOD financial health score despite current market challenges.
The expanded collaboration will focus on enhancing the accuracy, timeliness, and security of Continuity of Care Documents (CCDs), which are essential summaries of patient health information used for clinical decision-making and care coordination.
Health Catalyst will deploy its Ninja Universe technology, a parsing tool designed to streamline health data exchange throughout Nebraska’s healthcare network.
"Timely, accurate access to patient health data is essential to advancing care quality and achieving measurable healthcare improvement," said Dan Burton, CEO of Health Catalyst.
Dr. Jaime Bland, CEO & President of CyncHealth Nebraska, added that the partnership would help ensure "Nebraska clinicians get the information they need through CCDs for confident decision-making."
The initiative builds upon an existing relationship between the two organizations and aims to standardize how patient health information is parsed and shared across the state’s healthcare facilities.
CyncHealth operates as a health data utility connecting over 5 million lives and 1,100 facilities across Nebraska and Iowa, while Health Catalyst provides data and analytics technology to more than 1,000 healthcare organizations worldwide.
The partnership is expected to improve patient outcomes by enabling more efficient transmission of health information, particularly during care transitions or when patients are seeing multiple providers.
In other recent news, Health Catalyst reported a significant earnings per share (EPS) miss in its Q2 2025 earnings report, with an EPS of -$0.59 compared to the forecasted $0.04. Despite a minor revenue beat, the negative earnings surprise of -1575% was notable. Following this, Piper Sandler downgraded Health Catalyst’s stock rating from Overweight to Neutral, reducing the price target to $4.00 from $8.00 due to disappointing first-half 2025 bookings and a reduction in the company’s revenue guidance. Wells Fargo also lowered its price target to $6.00 from $10.00, maintaining an Overweight rating, as clients shift from bundled software to modular solutions, which is expected to continue impacting revenue through mid-2026. Canaccord Genuity further reduced its price target to $5.00 from $9.00, maintaining a Buy rating but reflecting adjusted expectations for the company’s growth. Meanwhile, Evercore ISI raised its price target to $4.00 from $3.00, noting the company’s efforts to roll out its Ignite platform and evolve its portfolio. These developments highlight ongoing adjustments in analyst expectations and strategic shifts within Health Catalyst.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.